Report Categories

According to our (Global Info Research) latest study, the global Biosimilar Insulin market size was valued at USD 2632.1 million in 2023 and is forecast to a readjusted size of USD 6421.8 million by 2030 with a CAGR of 13.6% during review period.

USD3480.00

Add To Cart

The global Biosimilar Insulin Lispro market size is expected to reach $ 633.5 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).

USD4480.00

Add To Cart

According to our (Global Info Research) latest study, the global Biosimilar Insulin Lispro market size was valued at USD 526.4 million in 2023 and is forecast to a readjusted size of USD 633.5 million by 2030 with a CAGR of 2.7% during review period.

USD3480.00

Add To Cart

The global Biosimilar Insulin Glargine market size is expected to reach $ 2533.8 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).

USD4480.00

Add To Cart

According to our (Global Info Research) latest study, the global Biosimilar Insulin Glargine market size was valued at USD 2105.6 million in 2023 and is forecast to a readjusted size of USD 2533.8 million by 2030 with a CAGR of 2.7% during review period.

USD3480.00

Add To Cart

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

USD3480.00

Add To Cart

The global Biosimilar Insulin Lispro market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

USD4480.00

Add To Cart

Insulin lispro Sanofi is a 'biosimilar medicine'. This means that it is highly similar to a biological medicine (also known as the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution

USD3480.00

Add To Cart

The global Biosimilar Insulin Glargine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

USD4480.00

Add To Cart

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

USD3480.00

Add To Cart